| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 1994 | 3-beta-D-ribofuranosyl-6,7-dihydro-9H-thiazolo[3,2-a]purin-9-one hydrate | Liaw, Y. C. ; Wang, A. H. J.; Lin, G. S.; Chern, J. W. | Acta Crystallogr C 50, 734-736 | | | |
| 1999 | Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM | Cheng, T. L.; Wu, P. Y.; Wu, M. F.; Chern, J. W.; Roffler, S. R. | Bioconjugate Chemistry 10, 520-528 | | | |
| 1991 | Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate | Roffler, S. R.; Wang, S. M.; Chern, J. W.; Yeh, M. Y.; Tung, E. | Biochem Pharmacol 42, 2062-2065 | | | |
| 2002 | Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice | Prijovich, Z. M.; Chen, B. M.; Leu, Y. L.; Chern, J. W.; Roffler, S. R. | British Journal of Cancer 86, 1634-1638 | | | |
| 1999 | Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug | Cheng, T. L.; Wei, S. L.; Chen, B. M.; Chern, J. W.; Wu, M. F.; Liu, P. W.; Roffler, S. R. | British Journal of Cancer 79, 1378-1385 | | | |
| 1999 | Characterization of an antineoplastic glucuronide prodrug | Cheng, T. L.; Chou, W. C.; Chen, B. M.; Chern, J. W.; Roffler, S. R. | Biochem Pharmacol 58, 325-328 | | | |
| 1997 | Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats | Chen, B. M.; Chan, L. Y.; Wang, S. M.; Wu, M. F.; Chern, J. W.; Roffler, S. R. | Int J Cancer 73, 392-402 | | | |
| 1999 | Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT) | Leu, Y. L.; Roffler, S. R.; Chern, J. W. | J Med Chem 42, 3623-3628 | | | |
| 2000 | Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy | Cheng, T. L.; Chen, B. M.; Chern, J. W.; Wu, M. F.; Roffler, S. R. | Bioconjugate Chemistry 11, 258-266 | | | |
| 1992 | Heterocyclic Compounds. I. Reactions of o-amino-carboxamide with b-diketones: Synthesis of Imidazo[1,5-a]pyrimidine and Pyrazolo[1,5-a]pyrimidine Derivatives | Chern, J. W.; Lee, C. C.; Liaw, Y. C. ; Wang, A. H. J. | Heterocycles 34, 1133-1145 | | | |
| 1997 | Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs | Cheng, T. L.; Chen, B. M.; Chan, L. Y.; Wu, P. Y.; Chern, J. W.; Roffler, S. R. | Cancer Immunol Immunother 44, 305-315 | | | |
| 2000 | Proactive antitumor compounds | Roffler, S. R.; Chern, J. W.; Leu, Y. L. | US Patent #6,043,367 | | | |
| 2003 | Proactive antitumor compounds | Roffler, S. R.; Chern, J. W.; Leu, Y. L. | European Patent EP0990661 | | | |
| 1992 | Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy | Wang, S. M.; Chern, J. W.; Yeh, M. Y.; Ng, J. C.; Tung, E.; Roffler, S. R. | Cancer Res 52, 4484-4491 | | | |
| 1993 | Studies on 1,2,4-Benzothiadiazine 1,1-dioxides VII and Quinazolinones IV: Synthesis of Novel Built-in Hydroxyguanine Tricycles as Potential Anticancer Agents | Chern, J. W.; Liaw, Y. C. ; Chen, C. S.; Rong, J. G.; Huang, C. L.; Chan, C. H.; Wang, A. H. J. | Heterocycles 36, 1091-1103 | | | |
| 1997 | Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents | Chern, J. W.; Leu, Y. L.; Wang, S. S.; Jou, R.; Lee, C. F.; Tsou, P. C.; Hsu, S. C.; Liaw, Y. C. ; Lin, H. M. | J Med Chem 40, 2276-2286 | | | |
| 1992 | Unusual conformational flexibility in N1-substituted uncommon purine nucleosides. Crystal structure of 1-allyl-isoguanosine and 1-allyl-xanthosine | Liaw, Y. C. ; Chern, J. W.; Lin, G. S.; Wang, A. H. J. | FEBS Lett 297, 4-8 | | | |
